Passage Bio
PASG
29 hedge funds and large institutions have $6.82M invested in Passage Bio in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 9 closing their positions.
11.9% less ownership
Funds ownership: 55.49% → 43.59% (-12%)
17% less funds holding
Funds holding: 35 → 29 (-6)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
51% less capital invested
Capital invested by funds: $13.8M → $6.82M (-$7.01M)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$670K |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$313K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$196K |
| 4 |
DAM
Deltec Asset Management
New York
|
+$93.8K |
| 5 |
HF
HRT Financial
New York
|
+$79.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$2.39M |
| 2 |
EP
Eversept Partners
New York
|
-$1.03M |
| 3 |
Renaissance Technologies
New York
|
-$536K |
| 4 |
EAM
Erste Asset Management
Vienna,
Austria
|
-$279K |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$153K |
PASG Hedge Fund Activity: Q2 2026 in Review
29 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2026, worth a combined $6.82M — down 51% from $13.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PASG and 4 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $670K. The largest seller was Vestal Point Capital, exiting entirely with an estimated $2.39M sold.
- 29 institutional investors held Passage Bio (PASG) as of Q2 2026, down from 35 in Q1 2026.
- Funds reported $6.82M of Passage Bio stock for Q2 2026, down 51% quarter-over-quarter.
- 4 funds opened new Passage Bio positions in Q2 2026 and 9 closed out, a net change of -5 holders.
- The largest Passage Bio buyer in Q2 2026 was Balyasny Asset Management, an estimated $670K added.
- The largest Passage Bio seller in Q2 2026 was Vestal Point Capital, an estimated $2.39M sold.
Based on aggregated 13F filings for Q2 2026.